Alpa Laboratories Limited
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
Alpa Laboratories Limited (ALPA) - Net Assets
Latest net assets as of September 2025: ₹1.83 Billion INR
Based on the latest financial reports, Alpa Laboratories Limited (ALPA) has net assets worth ₹1.83 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹2.38 Billion) and total liabilities (₹543.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹1.83 Billion |
| % of Total Assets | 77.14% |
| Annual Growth Rate | 15.97% |
| 5-Year Change | 59.26% |
| 10-Year Change | 83.54% |
| Growth Volatility | 57.12 |
Alpa Laboratories Limited - Net Assets Trend (2002–2025)
This chart illustrates how Alpa Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alpa Laboratories Limited (2002–2025)
The table below shows the annual net assets of Alpa Laboratories Limited from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹1.71 Billion | +12.85% |
| 2024-03-31 | ₹1.52 Billion | +12.88% |
| 2023-03-31 | ₹1.35 Billion | +10.55% |
| 2022-03-31 | ₹1.22 Billion | +13.09% |
| 2021-03-31 | ₹1.08 Billion | +7.24% |
| 2020-03-31 | ₹1.00 Billion | +1.91% |
| 2019-03-31 | ₹984.94 Million | +0.97% |
| 2018-03-31 | ₹975.49 Million | +2.98% |
| 2017-03-31 | ₹947.30 Million | +1.42% |
| 2016-03-31 | ₹934.05 Million | +7.91% |
| 2015-03-31 | ₹865.59 Million | -1.98% |
| 2014-03-31 | ₹883.06 Million | -5.52% |
| 2013-03-31 | ₹934.60 Million | -4.47% |
| 2012-03-31 | ₹978.28 Million | +0.54% |
| 2011-03-31 | ₹973.00 Million | +0.94% |
| 2010-03-31 | ₹963.96 Million | +0.83% |
| 2009-03-31 | ₹956.00 Million | +0.40% |
| 2008-03-31 | ₹952.21 Million | +254.51% |
| 2007-03-31 | ₹268.60 Million | +51.98% |
| 2006-03-31 | ₹176.73 Million | +136.31% |
| 2005-03-31 | ₹74.79 Million | +25.57% |
| 2004-03-31 | ₹59.56 Million | -0.31% |
| 2003-03-31 | ₹59.74 Million | +5.31% |
| 2002-03-31 | ₹56.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alpa Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 58736.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹954.33 Million | 55.67% |
| Common Stock | ₹210.41 Million | 12.27% |
| Other Components | ₹549.61 Million | 32.06% |
| Total Equity | ₹1.71 Billion | 100.00% |
Alpa Laboratories Limited Competitors by Market Cap
The table below lists competitors of Alpa Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IVVCL
SN:IVVCL
|
$5.55 Million |
|
Mason Graphite Inc.
OTCQB:MGPHF
|
$5.55 Million |
|
Binah Capital Group, Inc. Common Stock
NASDAQ:BCG
|
$5.55 Million |
|
Magnum Ventures Limited
NSE:MAGNUM
|
$5.55 Million |
|
Baltic Sea Properties AS
OL:BALT
|
$5.55 Million |
|
Hawthorn Resources Ltd
AU:HAW
|
$5.55 Million |
|
Power Line Engineering Public Company Limited
BK:PLE
|
$5.55 Million |
|
Stock Trend Capital Inc.
PINK:STOCF
|
$5.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alpa Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,519,096,000 to 1,714,341,000, a change of 195,245,000 (12.9%).
- Net income of 195,031,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,308,690,000.
- Other factors increased equity by 1,308,904,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹195.03 Million | +11.38% |
| Other Comprehensive Income | ₹-1.31 Billion | -76.34% |
| Other Changes | ₹1.31 Billion | +76.35% |
| Total Change | ₹- | 12.85% |
Book Value vs Market Value Analysis
This analysis compares Alpa Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.46x to 0.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹13.41 | ₹59.76 | x |
| 2006-03-31 | ₹31.37 | ₹59.76 | x |
| 2007-03-31 | ₹12.46 | ₹59.76 | x |
| 2008-03-31 | ₹45.26 | ₹59.76 | x |
| 2009-03-31 | ₹45.44 | ₹59.76 | x |
| 2010-03-31 | ₹45.81 | ₹59.76 | x |
| 2011-03-31 | ₹46.24 | ₹59.76 | x |
| 2012-03-31 | ₹46.50 | ₹59.76 | x |
| 2013-03-31 | ₹44.50 | ₹59.76 | x |
| 2014-03-31 | ₹41.97 | ₹59.76 | x |
| 2015-03-31 | ₹40.87 | ₹59.76 | x |
| 2016-03-31 | ₹44.34 | ₹59.76 | x |
| 2017-03-31 | ₹45.02 | ₹59.76 | x |
| 2018-03-31 | ₹46.36 | ₹59.76 | x |
| 2019-03-31 | ₹43.81 | ₹59.76 | x |
| 2020-03-31 | ₹47.70 | ₹59.76 | x |
| 2021-03-31 | ₹51.16 | ₹59.76 | x |
| 2022-03-31 | ₹57.86 | ₹59.76 | x |
| 2023-03-31 | ₹63.96 | ₹59.76 | x |
| 2024-03-31 | ₹72.53 | ₹59.76 | x |
| 2025-03-31 | ₹81.46 | ₹59.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alpa Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.38%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.34%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.30x
- Recent ROE (11.38%) is above the historical average (5.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.53% | 0.16% | 0.99x | 3.47x | ₹-5.37 Million |
| 2003 | 5.04% | 1.06% | 1.33x | 3.57x | ₹-2.96 Million |
| 2005 | 19.69% | 3.94% | 1.31x | 3.82x | ₹7.25 Million |
| 2006 | 23.34% | 5.85% | 1.33x | 3.01x | ₹23.57 Million |
| 2007 | 23.83% | 6.31% | 1.67x | 2.26x | ₹37.15 Million |
| 2008 | 7.27% | 5.36% | 0.86x | 1.57x | ₹-25.98 Million |
| 2009 | 0.40% | 0.31% | 0.77x | 1.66x | ₹-91.81 Million |
| 2010 | 0.83% | 0.85% | 0.67x | 1.46x | ₹-88.43 Million |
| 2011 | 0.93% | 1.09% | 0.64x | 1.33x | ₹-88.26 Million |
| 2012 | 0.54% | 0.96% | 0.42x | 1.33x | ₹-92.54 Million |
| 2013 | -4.67% | -7.78% | 0.45x | 1.33x | ₹-137.14 Million |
| 2014 | -5.84% | -9.09% | 0.45x | 1.43x | ₹-139.85 Million |
| 2015 | -1.61% | -2.44% | 0.45x | 1.48x | ₹-100.54 Million |
| 2016 | 7.33% | 12.77% | 0.37x | 1.54x | ₹-24.94 Million |
| 2017 | 2.66% | 4.03% | 0.50x | 1.33x | ₹-69.53 Million |
| 2018 | 2.86% | 4.51% | 0.51x | 1.25x | ₹-69.65 Million |
| 2019 | 1.03% | 1.32% | 0.63x | 1.23x | ₹-88.38 Million |
| 2020 | 1.85% | 2.18% | 0.70x | 1.21x | ₹-81.84 Million |
| 2021 | 6.73% | 7.52% | 0.69x | 1.30x | ₹-35.17 Million |
| 2022 | 11.58% | 12.75% | 0.71x | 1.28x | ₹19.19 Million |
| 2023 | 9.35% | 13.62% | 0.55x | 1.24x | ₹-8.75 Million |
| 2024 | 11.04% | 15.43% | 0.60x | 1.20x | ₹15.86 Million |
| 2025 | 11.38% | 17.34% | 0.51x | 1.30x | ₹23.60 Million |
Industry Comparison
This section compares Alpa Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $13,821,661,025
- Average return on equity (ROE) among peers: 16.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alpa Laboratories Limited (ALPA) | ₹1.83 Billion | 0.53% | 0.30x | $5.55 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |